Cargando…
Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome. Often, HE causes cognitive and motor dysfunctions due to an acute or chronic insufficiency of the liver or a shunting between the hepatic portal vein and systemic vasculature. Liver damage induces peripheral changes,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Revinter Publicações Ltda.
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371400/ https://www.ncbi.nlm.nih.gov/pubmed/37487550 http://dx.doi.org/10.1055/s-0043-1767819 |
_version_ | 1785078139162984448 |
---|---|
author | Santos, Rafaela Pinto Coelho Toscano, Eliana Cristina de Brito Rachid, Milene Alvarenga |
author_facet | Santos, Rafaela Pinto Coelho Toscano, Eliana Cristina de Brito Rachid, Milene Alvarenga |
author_sort | Santos, Rafaela Pinto Coelho |
collection | PubMed |
description | Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome. Often, HE causes cognitive and motor dysfunctions due to an acute or chronic insufficiency of the liver or a shunting between the hepatic portal vein and systemic vasculature. Liver damage induces peripheral changes, such as in the metabolism and peripheral inflammatory responses that trigger exacerbated neuroinflammation. In experimental models, anti-inflammatory strategies have demonstrated neuroprotective effects, leading to a reduction in HE-related cognitive and motor impairments. In this scenario, a growing body of evidence has shown that peripheral and central nervous system inflammation are promising preclinical targets. In this review, we performed an overview of FDA-approved drugs and natural compounds which are used in the treatment of other neurological and nonneurological diseases that have played a neuroprotective role in experimental HE, at least in part, through anti-inflammatory mechanisms. Despite the exciting results from animal models, the available data should be critically interpreted, highlighting the importance of translating the findings for clinical essays. |
format | Online Article Text |
id | pubmed-10371400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Thieme Revinter Publicações Ltda. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103714002023-07-27 Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies Santos, Rafaela Pinto Coelho Toscano, Eliana Cristina de Brito Rachid, Milene Alvarenga Arq Neuropsiquiatr Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome. Often, HE causes cognitive and motor dysfunctions due to an acute or chronic insufficiency of the liver or a shunting between the hepatic portal vein and systemic vasculature. Liver damage induces peripheral changes, such as in the metabolism and peripheral inflammatory responses that trigger exacerbated neuroinflammation. In experimental models, anti-inflammatory strategies have demonstrated neuroprotective effects, leading to a reduction in HE-related cognitive and motor impairments. In this scenario, a growing body of evidence has shown that peripheral and central nervous system inflammation are promising preclinical targets. In this review, we performed an overview of FDA-approved drugs and natural compounds which are used in the treatment of other neurological and nonneurological diseases that have played a neuroprotective role in experimental HE, at least in part, through anti-inflammatory mechanisms. Despite the exciting results from animal models, the available data should be critically interpreted, highlighting the importance of translating the findings for clinical essays. Thieme Revinter Publicações Ltda. 2023-07-24 /pmc/articles/PMC10371400/ /pubmed/37487550 http://dx.doi.org/10.1055/s-0043-1767819 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Santos, Rafaela Pinto Coelho Toscano, Eliana Cristina de Brito Rachid, Milene Alvarenga Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
title | Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
title_full | Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
title_fullStr | Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
title_full_unstemmed | Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
title_short | Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
title_sort | anti-inflammatory strategies for hepatic encephalopathy: preclinical studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371400/ https://www.ncbi.nlm.nih.gov/pubmed/37487550 http://dx.doi.org/10.1055/s-0043-1767819 |
work_keys_str_mv | AT santosrafaelapintocoelho antiinflammatorystrategiesforhepaticencephalopathypreclinicalstudies AT toscanoelianacristinadebrito antiinflammatorystrategiesforhepaticencephalopathypreclinicalstudies AT rachidmilenealvarenga antiinflammatorystrategiesforhepaticencephalopathypreclinicalstudies |